Even under some very generous assumptions of additional price cuts and a doubling of baseline use, we still see the dollars only stretching to cover ~ 30% of the newly eligible population
Semaglutide is a medication that belongs to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs) It is primarily used for the treatment of type 2 diabetes, but recent research has shown its potential in managing insulin resistance as well
With compounding off the table for routine use, cost questions turn to the approved product: Manufacturer savings: Depending on eligibility and insurance, manufacturer programs may reduce out-of-pocket costs (for some commercially insured patients, promotional materials describe as little as $0 offers up to a monthly maximum savings)
Anyone with cardiovascular conditions, orthopedic limitations, or a history of significant metabolic disruption should obtain physician clearance before beginning a progressive resistance program
[133] Patients should be educated about the importance of checking expiration dates regularly and should be instructed to dispose of expired medications through appropriate channels